SAVA

Cassava Sciences, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cassavasciences.com
Employees(FY) 26
ISIN US14817C1071

Performance

-15.77%

-91.61%

-92.26%

-87.95%

-89.56%

YTD

-91.53%

Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of SAVA 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. The Technical Score of 33 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SAVA

Stock Rank

Recent News & Updates

2024-12-16 01:55
Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky for More Information SAVA(Globenewswire)
2024-11-25 07:30
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints(GlobeNewswire)
2024-11-25 03:15
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops(Yahoo Finance)
2024-11-25 02:57
Cassava Sciences plummets over 80% on Alzheimer's trial fail(Yahoo Finance)
2024-11-24 20:19
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study(Investopedia)
2024-11-24 20:01
Cassava Sciences to Hold Corporate Update on November 25th(GlobeNewswire)
2024-11-24 18:30
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints(Globenewswire)
2024-11-24 07:01
Cassava Sciences to Hold Corporate Update on November 25th(Globenewswire)
2024-11-18 08:30
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer(GlobeNewswire)
2024-11-17 19:30
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer(Globenewswire)
2024-11-07 07:55
Cassava Sciences Reports Q3 2024 Financial and Operating Results(GlobeNewswire)
2024-11-06 18:55
Cassava Sciences Reports Q3 2024 Financial and Operating Results(Globenewswire)
2024-10-31 08:30
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024(GlobeNewswire)
2024-10-30 20:30
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024(Globenewswire)
2024-10-30 09:47
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value(Simply Wall St.)
2024-10-17 09:19
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge(Insidermonkey)
2024-10-09 08:29
Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement(TipRanks)
2024-09-27 15:36
Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims(Yahoo Finance Video)
2024-09-26 22:10
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims(Investopedia)
2024-09-26 18:15
Cassava Sciences Resolves SEC Investigation(GlobeNewswire)
2024-09-24 08:30
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials(GlobeNewswire)
2024-09-23 20:30
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials(Globenewswire)
2024-09-09 08:30
Cassava Sciences Names Rick Barry as Chief Executive Officer(GlobeNewswire)
2024-09-08 20:30
Cassava Sciences Names Rick Barry as Chief Executive Officer(Globenewswire)
2024-09-03 08:31
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference(GlobeNewswire)
2024-09-02 20:31
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference(Globenewswire)
2024-08-17 10:44
Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks(Insidermonkey)
2024-08-16 20:22
7 Best Debt Free Stocks To Buy(Insidermonkey)
2024-08-10 09:09
Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?(Simply Wall St.)
2024-08-08 08:00
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates(GlobeNewswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.